Professionals involved in:

• Real-World Evidence
• Real-World Data
• Epidemiology
• Policy
• Regulatory Science
• Technology development
• Data analytics
• Clinical Research

At the conclusion of this activity, participants should be able to:

• Explain how RWE is being used today to inform biopharmaceutic development across product lifecycle
• Discuss “lessons learned” from current uses of RWE by regulators, and how they can be applied for other future applications of RWE
• Recognize general considerations and key features of successful RWE studies acceptable to the regulators for effective decision-making
• Identify guidance and best practices for generating fit-for-purpose RWE for payers and HTA bodies
• Define the expanding applications of RWE to support clinical trials and evidence generation
• Evaluate the future applications of RWE in drug development
• Appraise how mobile technologies, artificial intelligence, machine learning, and other technologies are being used to generate RWE
• Evaluate how patient reported outcomes, electronic health records, and other patient data is expanding the resources for RWE